Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years.
In this study, we determined the diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers to predict development of Alzheimer's disease (AD) within five years in patients with mild cognitive impairment (MCI). To do so, the levels of tau, phosphorylated tau, Abeta42, Abeta40, Abeta38, sAbetaPPalpha, and sAbetaPPbeta were analyzed in 327 CSF samples obtained at baseline from patients with AD (n=